Share Email Print
cover

Proceedings Paper

Noninvasive point-of-care measurement of gastrointestinal permeability
Author(s): Richard B. Dorshow; J. R. Johnson; Martin P. Debreczeny; I. Rochelle Riley; Jeng-Jong Shieh; Thomas E. Rogers; Carla Hall-Moore; Nurmohammad Shaikh; Phillip I. Tarr
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

The intestinal mucosal barrier prevents macromolecules and pathogens from entering the circulatory stream in a healthy gut. Tight junctions in this barrier are compromised in many intestinal disorders including inflammatory bowel diseases (such as Crohn’s and ulcerative colitis), celiac disease, graft vs host disease, environmental enteropathy, and enteric dysfunction. Dual sugar absorption tests are a standard method for measuring gastrointestinal integrity in humans. The larger molecular weight sugar, lactulose, is minimally absorbed through a healthy gut. The smaller molecular weight sugar, mannitol or rhamnose, in contrast, is readily absorbed through both a healthy and inflamed gut. Thus, a higher ratio of lactulose to mannitol or rhamnose reflects increased intestinal permeability. However, several issues prevent the widespread use of the dual sugar assay including requirements for lengthy urine collection, transport of specimens under conditions free from contamination and bacterial growth, analysis by sophisticated laboratory equipment, and the associated lengthy turnaround time. In a recent publication, the feasibility of employing a dual fluorescent tracer agent assay to mimic the dual sugar absorption test without the need for specimen collection was reported. This dual fluorophore assay for GI permeability was demonstrated in an indomethacin-induced bowel disease model in rats. However, one of the fluorophores was not entirely biocompatible. Herein is reported a dual fluorophore system that is totally biocompatible, with emphasis on the transdermal detection of the fluorophores, thus enabling the use of the technology for noninvasive point-of-care gastrointestinal permeability determination.

Paper Details

Date Published: 7 March 2019
PDF: 7 pages
Proc. SPIE 10893, Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications XI, 1089307 (7 March 2019); doi: 10.1117/12.2507965
Show Author Affiliations
Richard B. Dorshow, MediBeacon Inc. (United States)
J. R. Johnson, MediBeacon Inc. (United States)
Martin P. Debreczeny, MediBeacon Inc. (United States)
I. Rochelle Riley, MediBeacon Inc. (United States)
Jeng-Jong Shieh, MediBeacon Inc. (United States)
Thomas E. Rogers, MediBeacon Inc. (United States)
Carla Hall-Moore, Washington Univ. School of Medicine in St. Louis (United States)
Nurmohammad Shaikh, Washington Univ. School of Medicine in St. Louis (United States)
Phillip I. Tarr, Washington Univ. School of Medicine in St. Louis (United States)


Published in SPIE Proceedings Vol. 10893:
Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications XI
Samuel Achilefu; Ramesh Raghavachari, Editor(s)

© SPIE. Terms of Use
Back to Top